204 related articles for article (PubMed ID: 21629671)
1. Potential role of cathepsin K in the pathophysiology of mucopolysaccharidoses.
Wilson S; Brömme D
J Pediatr Rehabil Med; 2010; 3(2):139-46. PubMed ID: 21629671
[TBL] [Abstract][Full Text] [Related]
2. Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities.
Wilson S; Hashamiyan S; Clarke L; Saftig P; Mort J; Dejica VM; Brömme D
Am J Pathol; 2009 Nov; 175(5):2053-62. PubMed ID: 19834056
[TBL] [Abstract][Full Text] [Related]
3. Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates.
Li Z; Hou WS; Brömme D
Biochemistry; 2000 Jan; 39(3):529-36. PubMed ID: 10642177
[TBL] [Abstract][Full Text] [Related]
4. Regulation of collagenase activities of human cathepsins by glycosaminoglycans.
Li Z; Yasuda Y; Li W; Bogyo M; Katz N; Gordon RE; Fields GB; Brömme D
J Biol Chem; 2004 Feb; 279(7):5470-9. PubMed ID: 14645229
[TBL] [Abstract][Full Text] [Related]
5. Growth impairment in mucopolysaccharidoses.
Melbouci M; Mason RW; Suzuki Y; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2018 May; 124(1):1-10. PubMed ID: 29627275
[TBL] [Abstract][Full Text] [Related]
6. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation.
Opoka-Winiarska V; Jurecka A; Emeryk A; Tylki-Szymańska A
Osteoarthritis Cartilage; 2013 Dec; 21(12):1813-23. PubMed ID: 23954699
[TBL] [Abstract][Full Text] [Related]
7. Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate.
Li Z; Hou WS; Escalante-Torres CR; Gelb BD; Bromme D
J Biol Chem; 2002 Aug; 277(32):28669-76. PubMed ID: 12039963
[TBL] [Abstract][Full Text] [Related]
8. Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease.
Motyckova G; Fisher DE
Curr Mol Med; 2002 Aug; 2(5):407-21. PubMed ID: 12125807
[TBL] [Abstract][Full Text] [Related]
9. Novel roles of glycosaminoglycans in the degradation of type I collagen by cathepsin K.
Tatara Y; Suto S; Itoh K
Glycobiology; 2017 Dec; 27(12):1089-1098. PubMed ID: 29029096
[TBL] [Abstract][Full Text] [Related]
10. Binding of heparan sulfate to human cystatin C modulates inhibition of cathepsin L: Putative consequences in mucopolysaccharidosis.
Denamur S; Chazeirat T; Maszota-Zieleniak M; Vivès RR; Saidi A; Zhang F; Linhardt RJ; Labarthe F; Samsonov SA; Lalmanach G; Lecaille F
Carbohydr Polym; 2022 Oct; 293():119734. PubMed ID: 35798429
[TBL] [Abstract][Full Text] [Related]
11. Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses.
Cotugno G; Tessitore A; Capalbo A; Annunziata P; Strisciuglio C; Faella A; Aurilio M; Di Tommaso M; Russo F; Mancini A; De Leonibus E; Aloj L; Auricchio A
Hum Gene Ther; 2010 May; 21(5):555-69. PubMed ID: 20021231
[TBL] [Abstract][Full Text] [Related]
12. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
[TBL] [Abstract][Full Text] [Related]
13. UPLC-MS/MS detection of disaccharides derived from glycosaminoglycans as biomarkers of mucopolysaccharidoses.
Auray-Blais C; Lavoie P; Tomatsu S; Valayannopoulos V; Mitchell JJ; Raiman J; Beaudoin M; Maranda B; Clarke JT
Anal Chim Acta; 2016 Sep; 936():139-48. PubMed ID: 27566349
[TBL] [Abstract][Full Text] [Related]
14. Arylsulfatase K inactivation causes mucopolysaccharidosis due to deficient glucuronate desulfation of heparan and chondroitin sulfate.
Trabszo C; Ramms B; Chopra P; Lüllmann-Rauch R; Stroobants S; Sproß J; Jeschke A; Schinke T; Boons GJ; Esko JD; Lübke T; Dierks T
Biochem J; 2020 Sep; 477(17):3433-3451. PubMed ID: 32856704
[TBL] [Abstract][Full Text] [Related]
15. Glycosaminoglycan storage disorders: a review.
Coutinho MF; Lacerda L; Alves S
Biochem Res Int; 2012; 2012():471325. PubMed ID: 22013531
[TBL] [Abstract][Full Text] [Related]
16. The crystal and molecular structures of a cathepsin K:chondroitin sulfate complex.
Li Z; Kienetz M; Cherney MM; James MN; Brömme D
J Mol Biol; 2008 Oct; 383(1):78-91. PubMed ID: 18692071
[TBL] [Abstract][Full Text] [Related]
17. Newborn screening and diagnosis of mucopolysaccharidoses: application of tandem mass spectrometry.
Tomatsu S; Kubaski F; Sawamoto K; Mason RW; Yasuda E; Shimada T; Montaño AM; Yamaguchi S; Suzuki Y; Orii T
Nihon Masu Sukuriningu Gakkai Shi; 2014; 24():19-37. PubMed ID: 25620850
[TBL] [Abstract][Full Text] [Related]
18. Altered interaction and distribution of glycosaminoglycans and growth factors in mucopolysaccharidosis type I bone disease.
Kingma SDK; Wagemans T; IJlst L; Bronckers ALJJ; van Kuppevelt TH; Everts V; Wijburg FA; van Vlies N
Bone; 2016 Jul; 88():92-100. PubMed ID: 27105565
[TBL] [Abstract][Full Text] [Related]
19. Two-dimensional NMR spectroscopy of urinary glycosaminoglycans from patients with different mucopolysaccharidoses.
Hochuli M; Wüthrich K; Steinmann B
NMR Biomed; 2003 Jun; 16(4):224-36. PubMed ID: 14558120
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of the mucopolysaccharidoses.
Lehman TJ; Miller N; Norquist B; Underhill L; Keutzer J
Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v41-8. PubMed ID: 22210670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
